JP2023546657A - Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 - Google Patents

Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 Download PDF

Info

Publication number
JP2023546657A
JP2023546657A JP2023523033A JP2023523033A JP2023546657A JP 2023546657 A JP2023546657 A JP 2023546657A JP 2023523033 A JP2023523033 A JP 2023523033A JP 2023523033 A JP2023523033 A JP 2023523033A JP 2023546657 A JP2023546657 A JP 2023546657A
Authority
JP
Japan
Prior art keywords
antibody
cancer
patient
csf
csf antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546657A5 (https=
Inventor
ジョー ピレロ，
エベン テッサリ，
ルイス カルバハル，
アンナリーサ ダンドレア，
Original Assignee
キニクサ ファーマシューティカルズ， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キニクサ ファーマシューティカルズ， リミテッド filed Critical キニクサ ファーマシューティカルズ， リミテッド
Publication of JP2023546657A publication Critical patent/JP2023546657A/ja
Publication of JP2023546657A5 publication Critical patent/JP2023546657A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2023523033A 2020-10-26 2021-10-26 Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 Pending JP2023546657A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063105773P 2020-10-26 2020-10-26
US63/105,773 2020-10-26
US202063120319P 2020-12-02 2020-12-02
US63/120,319 2020-12-02
US202163242849P 2021-09-10 2021-09-10
US63/242,849 2021-09-10
PCT/US2021/056700 WO2022093855A1 (en) 2020-10-26 2021-10-26 Treatment of cancers with gm-csf antagonists

Publications (2)

Publication Number Publication Date
JP2023546657A true JP2023546657A (ja) 2023-11-07
JP2023546657A5 JP2023546657A5 (https=) 2024-11-05

Family

ID=78820846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523033A Pending JP2023546657A (ja) 2020-10-26 2021-10-26 Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療

Country Status (6)

Country Link
US (1) US20220184179A1 (https=)
EP (1) EP4232162A1 (https=)
JP (1) JP2023546657A (https=)
KR (1) KR20230095983A (https=)
AU (1) AU2021372454A1 (https=)
WO (1) WO2022093855A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240309079A1 (en) * 2023-03-14 2024-09-19 Taran Therapeutics, Inc. Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations
WO2025096692A2 (en) * 2023-11-01 2025-05-08 Taran Therapeutics, Inc. Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097321A1 (en) * 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4943044B2 (ja) 2005-07-20 2012-05-30 リンテック株式会社 粘着シート
MX2008012291A (es) 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2013026059A1 (en) * 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
CA2851322C (en) 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
CN106456761A (zh) 2014-05-19 2017-02-22 免疫医疗有限公司 对类风湿关节炎的治疗
EP3786293A1 (en) 2015-06-12 2021-03-03 AxioMx, Inc. Methods and compositions for producing a chimeric polypeptide
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
AU2018345751A1 (en) * 2017-10-02 2020-05-07 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
CN109120869B (zh) * 2018-11-07 2024-09-06 深圳市道通智能航空技术股份有限公司 双光图像整合方法、整合设备及无人机
US20220331425A1 (en) * 2019-06-03 2022-10-20 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097321A1 (en) * 2018-11-09 2020-05-14 Kiniksa Pharmaceuticals, Ltd. Treatment for giant cell arteritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. Vol.134, Supplement_1, No.4234, JPN6025045095, 2019, pages 1 - 3, ISSN: 0005722964 *

Also Published As

Publication number Publication date
AU2021372454A1 (en) 2023-06-22
KR20230095983A (ko) 2023-06-29
WO2022093855A1 (en) 2022-05-05
US20220184179A1 (en) 2022-06-16
AU2021372454A9 (en) 2024-09-12
EP4232162A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
JP7464644B2 (ja) Ｐｄ－ｌ１及びｌａｇ－３に結合する結合分子
JP7155403B2 (ja) 抗ｇｄｆ１５抗体、組成物および使用の方法
US10487150B2 (en) SIRP alpha-antibody fusion proteins
KR102662228B1 (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
JP2021130709A (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
KR20210030956A (ko) Pd-l1 및 cd137에 결합하는 항체 분자
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
JP2025013608A (ja) Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
JP2024167278A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
CN116194105A (zh) 治疗癌症的方法、疗法及用途
JP2023546657A (ja) Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療
KR20240130705A (ko) Il-7 단백질 및 vegf 길항제의 조합으로 종양을 치료하는 방법
CN116685352A (zh) 用gm-csf拮抗剂治疗癌症
TW202222834A (zh) Ｐｄ－ｌ１抗體及其應用
HK40057934A (en) Binding molecules binding pd-l1 and lag-3
HK40085178A (en) Methods, therapies and uses for treating cancer
HK1238573B (en) Sirp alpha-antibody fusion proteins
HK1238573A1 (en) Sirp alpha-antibody fusion proteins
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241025

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260424